Could the next pertussis vaccine be intranasal?
A phase 2b trial in children aged 6–17 found BPZE1, a live attenuated intranasal vaccine, immunogenic and well tolerated.
Clinical efficacy and impact on transmission still need to be shown.
👇
doi: 10.1016/S1473-3099(26)00470-6.
#Pertussis #Vaccines